Get the Stockscreener App
67.34
1.29%
-0.88
After Hours:
67.34
Hologic Inc stock is traded at $67.34, with a volume of 1.08M.
It is down -1.29% in the last 24 hours and up +0.87% over the past month.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
See More
Previous Close:
$68.22
Open:
$68.22
24h Volume:
1.08M
Relative Volume:
0.58
Market Cap:
$14.98B
Revenue:
$4.03B
Net Income/Loss:
$556.70M
P/E Ratio:
28.41
EPS:
2.37
Net Cash Flow:
$970.10M
1W Performance:
+0.28%
1M Performance:
+0.87%
6M Performance:
+10.65%
1Y Performance:
-16.08%
1-Day Range:
$66.94
$68.22
1-Week Range:
$66.32
$69.13
52-Week Range:
$51.90
$84.39
Hologic Inc Stock (HOLX) Company Profile
Name
Hologic Inc
Sector
Industry
Phone
(508) 263-2900
Address
250 CAMPUS DRIVE, MARLBOROUGH, MA
Compare HOLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
67.34 | 15.17B | 4.03B | 556.70M | 970.10M | 2.37 |
|
ISRG
Intuitive Surgical Inc
|
449.69 | 162.16B | 9.15B | 2.63B | 1.99B | 7.1661 |
|
BDX
Becton Dickinson Co
|
191.99 | 55.49B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
RMD
Resmed Inc
|
281.38 | 40.66B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
ALC
Alcon Inc
|
76.82 | 38.26B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
WST
West Pharmaceutical Services Inc
|
268.07 | 19.60B | 2.96B | 487.70M | 344.00M | 6.68 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-25 | Upgrade | Argus | Hold → Buy |
| Aug-06-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-27-25 | Reiterated | Needham | Hold |
| Mar-03-25 | Downgrade | Argus | Buy → Hold |
| Feb-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-03-25 | Downgrade | Needham | Buy → Hold |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Dec-10-24 | Reiterated | Needham | Buy |
| Oct-01-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-24 | Initiated | Stephens | Overweight |
| Apr-03-24 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-23 | Upgrade | Needham | Hold → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-20-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-20-22 | Initiated | UBS | Neutral |
| Jul-18-22 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Oct-14-21 | Initiated | Redburn | Neutral |
| Jul-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-20-20 | Downgrade | Needham | Buy → Hold |
| Nov-05-20 | Reiterated | Needham | Buy |
| Jun-30-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-03-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-30-20 | Reiterated | Needham | Buy |
| Apr-30-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Apr-07-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Jan-31-19 | Reiterated | Needham | Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-09-18 | Initiated | UBS | Neutral |
| Sep-13-18 | Downgrade | BofA/Merrill | Buy → Neutral |
View All
Hologic Inc Stock (HOLX) Latest News
What to do if you’re stuck in Hologic Inc.Earnings Overview Summary & AI Powered Market Entry Ideas - newser.com
How Hologic Inc. (HO1) stock reacts to monetary easingEarnings Growth Summary & Growth-Oriented Investment Plans - newser.com
How to Play HOLX Stock This Breast Cancer Awareness Month? - Yahoo
Technical analysis overview for Hologic Inc. stock2025 Historical Comparison & Weekly Watchlist for Hot Stocks - newser.com
Will Dual FDA and CE Approvals for Panther Fusion Shape Hologic's (HOLX) Long-Term Story? - simplywall.st
What dividend safety rating applies to Hologic Inc. (HO1) stockWeekly Trend Summary & Weekly Top Gainers Alerts - newser.com
Should I buy Hologic Inc. (HO1) stock before earnings seasonPortfolio Return Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Greenleaf Trust Purchases 173 Shares of Hologic, Inc. $HOLX - Defense World
Chart based analysis of Hologic Inc. trendsTake Profit & Fast Momentum Entry Tips - newser.com
Is Hologic Inc. stock a buy before product launchesPortfolio Performance Report & Entry Point Confirmation Signals - newser.com
Key metrics from Hologic Inc.’s quarterly dataJuly 2025 Levels & Proven Capital Preservation Tips - newser.com
HOLX Stock Gains on FDA & CE Approval for Automated Molecular GI Tests - Yahoo
Risk adjusted return profile for Hologic Inc. analyzed2025 Year in Review & Fast Exit and Entry Strategy Plans - newser.com
Farther Finance Advisors LLC Increases Stock Position in Hologic, Inc. $HOLX - Defense World
User - FinancialContent
Is Hologic Inc. stock trading near support levelsEntry Point & High Return Trade Guides - newser.com
Why Hologic (HOLX) Outpaced the Stock Market Today - sharewise.com
Hologic Panther Fusion GI Assays - Infectious Disease Special Edition
Press Release: Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2025 on Monday, November 3, 2025 - 富途牛牛
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2025 on Monday, November 3, 2025 - The Globe and Mail
Hologic (HOLX): Assessing Valuation Following Upbeat Earnings, Guidance Boost, and New Partnership Moves - Yahoo Finance
Hologic gains FDA clearance for GI pathogen detection assays - Medical Device Network
New Data on AI-Powered Mammography Technology Presented at European Breast Imaging Meeting - Imaging Technology News
Hologic Earns FDA, EU Nods for Infectious Gastroenteritis Tests - Medical Product Outsourcing
FDA Clears Hologic's (HOLX) New Diagnostic Assays - GuruFocus
Hologic Receives FDA Clearance and CE Mark for Automated Molecular Tests to Detect Common Causes of Infectious GastroenteritisHologic, Inc. - Hologic, Inc. - Investor Relations
Hologic Bets on Endomagnetics to Fuel Interventional Breast Momentum - The Globe and Mail
Park Avenue Securities LLC Sells 2,368 Shares of Hologic, Inc. $HOLX - Defense World
Hologic jumps after report Blackstone, TPG have revived takeover interest - MSN
Minicarm.com to distribute Hologic’s Fluoroscan Insight FD mini C-arm in U.S. - DOTmed
Why Hologic (HOLX) is a Top Momentum Stock for the Long-Term - sharewise.com
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
New Survey Results Underscore the Need to #BustTheMyth About MammogramsHologic, Inc. - Hologic, Inc. - Investor Relations
MA-HOLOGIC-INC - The Facts
Hologic Inc Stock (HOLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Hologic Inc Stock (HOLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MACMILLAN STEPHEN P | Chairman, President and CEO |
Sep 22 '25 |
Sale |
66.97 |
138,358 |
9,266,118 |
1,234,624 |
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):